Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Uterine Cancer: early-phase trial registry
15 of 28 indexed Uterine Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #577 of 28,707 conditions by registered trial count.
28 US clinical trials · 15 currently recruiting · #577 of 28,707 conditions by registered trial count
Uterine Cancer: 28 US clinical trials tracked, 15 recruiting.
Uterine Cancer is the subject of 28 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 3 of these trials.
Enrollment posture brief
Registry condition uterine-cancer
OPEN 15 | RECR 54% | LATE 0 | EARLY 15 | RANK #577 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Wounds and Injuries (54% recruiting · 28 trials)
Uterine Cancer lists 15 open slots (54% of 28 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Uterine Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Uterine Cancer is recruiting above its size-band peers.
15 of 28 indexed trials (53.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Uterine Cancer trials is spread across many organizations.
Dana-Farber Cancer Institute accounts for 3 of 28 trials (10.7%). 20 distinct sponsors appear on at least one study for this condition label.
-
Most Uterine Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 37 among the 28 trials that report a genuine target (sentinel values excluded). 23 of those (82.1%) plan for fewer than 100 participants.
-
Uterine Cancer research is mostly interventional.
23 interventional and 5 observational studies make up this index (82.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
28 total, page 1 of 1
Investigations of Reproductive Cancers in Women
PinkDx
NCT06527157
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
Northwestern University
NCT05743517
Study of NEO-201 in Solid Tumors Expansion Cohorts
Precision Biologics
NCT03476681
Image-Guided Gynecologic Brachytherapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02993900
Molecular and Cellular Profiling of Uterine Lavage Collected During Gynecologic Surgery
Stanford University
NCT07044505
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
NCT04038619
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
University of Alabama at Birmingham
NCT05559879
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Washington University School of Medicine
NCT06795009
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Dana-Farber Cancer Institute
NCT06677190
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
Northwestern University
NCT05990426
[18F]FES PET/.CT in Uterine Cancer
Abramson Cancer Center at Penn Medicine
NCT05916196
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Joyce Liu, MD
NCT06369155
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
Abramson Cancer Center at Penn Medicine
NCT05758688
Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking
Duke University
NCT05977621
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Washington University School of Medicine
NCT06904365
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics
NCT05864144
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
Dana-Farber Cancer Institute
NCT03668340
Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer
Rutgers, The State University of New Jersey
NCT05220033
PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
Labcorp Corporation of America Holdings
NCT05697198
A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping
Novadaq Technologies ULC, now a part of Stryker
NCT02209532
Assisted Exercise in Obese Endometrial Cancer Patients
Case Comprehensive Cancer Center
NCT01870947
Image-Guided Gynecologic Brachytherapy
Dana-Farber Cancer Institute
NCT01399658
Interventions to Decrease Financial Toxicity
University of Alabama at Birmingham
NCT05939440
A Study of Nivolumab in Selected Uterine Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT03241745
A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
University of Alabama at Birmingham
NCT00584857
Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors
Memorial Sloan Kettering Cancer Center
NCT00588276
Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers
Holy Name Medical Center
NCT03604653
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
St. Luke's-Roosevelt Hospital Center
NCT01163552
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on Uterine Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Uterine Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Uterine Cancer page
28 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Uterine Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dana-Farber Cancer Institute sponsors the most Uterine Cancer trials on record, review their full trial history before evaluating a specific study. See Dana-Farber Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Uterine Cancer condition card totals 28 registered trials; most-linked intervention Proactive Cost of Care (P-COC) intervention; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.